News | December 07, 2022
Concord Biotech gets SEBI nod for IPO
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of US $512 million for twelve months ending Sep 2022 according to IQVIA
The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
40,000 visitors and representatives of more than 80 countries set to visit the show
Subscribe To Our Newsletter & Stay Updated
